Vi Launches Enterprise AI Agents; Closes $145M at $1.64B Valuation
Today we are launching a new suite of AI agents designed to serve as the execution layer for health, life sciences, and wellness enterprises. In parallel, we have raised $145 Million valuing the company at $1.64 Billion.
Why health abundance matters
The science is there. The treatments are there. The data is there. The system that delivers them is broken. A century of progress can happen in the next five years if execution catches up with the science. Every person should have access to the most precise, predictive care medicine can deliver. Health abundance in our lifetime is the outcome we’re working toward.
What we are building
Vi agents are fully integrated across our platform – Activate, Engage, Operate – and are built to drive next best actions across patients, care teams and operational workflows.
Unlike horizontal AI tools, Vi’s agents are vertically specialized for healthcare and life sciences, leveraging the Vi data web – one of the world’s largest datasets of clinical, behavioral, and operational signals. These agents are powered by productized, domain-specific models and are deployed compliantly on top of existing systems of record, enabling real-time decisioning and measurable ROI across use cases such as patient care navigation, physician next-best actions, clinical trial acceleration, drug commercialization, and supply chain optimization.
At scale
Today, we work with more than 100+ enterprise customers, including Fortune 500 companies and many of the world’s leading healthcare, life sciences, and wellness organizations. Through these partnerships, we’ve supported more than 190 million patients and members, and contributed to the development and commercialization of more than 50 drugs across oncology, pediatric epilepsy, and diabetes, and generated over $2 billion in measurable value.
Continuing to build
In parallel, we completed a $145 million transaction valuing Vi at $1.64 billion. The transaction consisted of both secondary and primary capital, aimed at supporting top talent retention and acquisition, investing in our platform and new products, and strengthening our balance sheet.
Health abundance in our lifetime is possible — a future where every person, regardless of wealth or geography, has access to the most precise, predictive, and affordable care medicine can deliver.
We’re grateful for the continued support of our shareholders, including General Atlantic, Revelstoke, 1902 Capital managed by The Pritzker Organization, Square Peg, Savano Capital, Island Green and others.